ArticleInternational journal of hematology2025
Histological confirmation and radiotherapy facilitate continuation of epcoritamab in a patient with tumor flare reaction.
Article in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Pseudoprogression of extramedullary lesions during elranatamab therapy in relapsed or refractory multiple myeloma.Journal of clinical and experimental hematopathology : JCEH · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epcoritamab, a CD3 × CD20 bispecific antibody, has been approved as salvage therapy for patients with relapsed/refractory large B-cell lymphoma. However, immunotherapeutic agents have been linked to tumor flare reaction (TFR), which is characterized by rapid tumor proliferation associated with the immune response. This report describes the case of a 71-year-old man with relapsed/refractory diffuse large B-cell lymphoma who developed TFR in the cervical lymph nodes during treatment with epcoritamab. Prompt biopsy upon detection of tumor enlargement led to an accurate diagnosis of TFR and informed therapeutic strategies. Subsequent radiotherapy (RT) effectively controlled local lesions while preserving the systemic immune response, suggesting that RT may be an option to prevent the recurrence and progression of TFR and help to avoid discontinuation of effective therapy.
Indexed as
Identifiers
40155558What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.